Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 and PD-1 Monoclonal Antibody in Advanced Solid Tumors
NCT06475300Phase 2Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Jun 2024
- Primary completion
- Jun 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of izalontamab brengitecan in non-small cell lung cancer (NSCLC), nasopharyngeal carcinoma (NPC) and solid tumor, sponsored by Biokin Pharmaceutical. Primary endpoints: Objective Response Rate at 24 months and Recommended Phase II Dose at 24 months. Started Jun 2024; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
non-small cell lung cancer (NSCLC)nasopharyngeal carcinoma (NPC)solid tumor
Beyond the preview
Go deeper on NCT06475300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06475300.